To gain insight into the immunomodulatory effects generated by administering nAChR antagonists during pulmonary tuberculosis, mice were treated with the α4β2 antagonist DHβE, 60 days after infection. This evidence concerns the gene CHRNA4 and pulmonary tuberculosis.